Video

Dr. Khetrapal discusses intracorporeal robotic vs open cystectomy

Author(s):

Urology Times staff
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Pramit Khetrapal, MD, academic clinical fellow in Urology, Barts Health NHS Trust compares intracorporeal robot-assisted radical cystectomy (iRARC) with open RC. At the 2022 AUA Annual Meeting, Khetrapal presented the abstract, “Results of the intracorporeal robotic vs open cystectomy (IROC) multi-centre randomised trial.”

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Vignesh Packiam, MD, on choosing between options in NMIBC
      Vignesh Packiam, MD, on choosing between options in NMIBC
      Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
      Strategies to bridge gender disparities in AAS and citations in the oncology literature
      4 experts in this video
      Case 3: A 49-Year-Old Man With Recurrent Non–Muscle-Invasive Bladder Cancer
      4 experts in this video
      Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
      Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
      Study findings highlight gender gaps in oncology authorship and citation
      4 experts in this video
      Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder Cancer
      4 experts in this video
      Non–Muscle Invasive-Bladder Cancer Overview
      Laura Davis, MD, on link between microplastics and bladder cancer
      Laura Davis, MD, on link between microplastics and bladder cancer
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Related Content
      From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance
      June 16th 2025

      From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance

      Anne K. Schuckman, MD Hannah Clarke
      Anne K. Schuckman, MD, describes the growing number of options in NMIBC and the impact of these therapies on clinical practice.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
      June 12th 2025

      FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC

      Hannah Clarke
      The approval is supported by findings from the phase 3 ENVISION trial.
      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
      December 7th 2021

      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

      Urology Times staff
      “It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      June 9th 2025

      En bloc resection of bladder tumor: Is it the way forward?

      Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery)
      "As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).
      Survey: New NMIBC treatments face slow uptake
      June 2nd 2025

      Survey: New NMIBC treatments face slow uptake

      Benjamin P. Saylor
      Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.
      © 2025 MJH Life Sciences

      All rights reserved.